Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats.
Drug candidates under development by industry frequently show phospholipidosis as a side-effect in pre-clinical toxicity studies. This study sets up a cell-based assay for drug-induced phospholipidosis (PLD) and its performance was evaluated based on the in vivo PLD potential of compounds in 2-week toxicity studies in rats. When HepG2 cells were exposed simultaneously to PLD-inducing chemicals and a phospholipid having a fluorophore, an accumulation of phospholipids was detected as an increasing fluorescent intensity. Amiodarone, amitriptyline, fluoxetine, AY-9944, and perhexiline, which are common PLD-inducing chemicals, increased the fluorescent intensity, but acetaminophen, ampicillin, cimetidine, famotidine, or valproic acid, which are non-PLD-inducing chemicals, did not. The fluorescent intensity showed concordance with the pathological observations of phospholipid lamellar bodies in the cells. Then to confirm the predictive performance of the in vitro PLD assay, the 32 proprietary compounds characterized in 2-week toxicity studies in rats were evaluated with this in vitro assay. Because this in vitro assay was vulnerable to cytotoxicity, the innate PLD potential was calculated for each compound. A statistically significant increase in the in vitro PLD potential was seen for the compounds having in vivo PLD-inducing potential in the rat toxicity studies. The results suggest that the in vitro PLD potential could be appropriate to detect the appearance of PLD as a side effect in pre-clinical toxicity studies in rats.
Development Research Center, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Osaka, Japan. miyamoto_saku@takeda.co.jp
Saku
S
Miyamoto
Akemi
A
Matsumoto
Ikuo
I
Mori
Akira
A
Horinouchi
D000638:Amiodarone / Q000633:toxicity; D000826:Animal Testing Alternatives / Q000379:methods; D000818:Animals; D022162:Cytoplasmic Vesicles / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000633:toxicity; D005260:Female; D005456:Fluorescent Dyes / Q000378:metabolism*; D056945:Hep G2 Cells; D006801:Humans; D008064:Lipidoses / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D046529:Microscopy, Electron, Transmission; D009928:Organ Specificity / Q000187:drug effects; D010714:Phosphatidylethanolamines / Q000378:metabolism*; D010743:Phospholipids / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013050:Spectrometry, Fluorescence; D013997:Time Factors; D018675:Toxicity Tests / Q000191:economics / Q000379:methods*
D004791:Enzyme Inhibitors; D005456:Fluorescent Dyes; D010714:Phosphatidylethanolamines; D010743:Phospholipids; C042077:N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)phosphatidylethanolamine; D000638:Amiodarone